Antiepileptic drugs and pregnancy outcomes

American Journal of Medical Genetics, Part A

Volumn 158 A, Issue 8, 2012, Pages 2071-2090

  Wlodarczyk, Bogdan J ^a   Palacios, Ana M ^a   George, Timothy M ^b   Finnell, Richard H ^a,c  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b DELL INC   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Antiepileptic drugs; Birth defects; Epilepsy; Pregnancy; Teratogenicity

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; DI PHEN; EQUETROL; ETIRACETAM; FANATREX; FOLIC ACID; FOLINIC ACID; GABAPENTIN; GABAPENTIN ENACARBIL; GABARONE; KAPPRA; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; SABRII; SOLFOTON; TOPIRAGEN; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VIGABATRIN;

ABSENCE; BIPOLAR DISORDER; COGNITION; COGNITIVE DEFECT; CONGENITAL MALFORMATION; DISEASE CONTROL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; EPILEPSY; EXPERIMENTAL STUDY; FIBROMYALGIA; FOCAL EPILEPSY; FOOD AND DRUG ADMINISTRATION; HUMAN; INFANTILE SPASM; LANGUAGE ABILITY; MIGRAINE; MYOCLONUS SEIZURE; NEOPLASM; NEUROPATHIC PAIN; NONHUMAN; PAIN; PANIC; POSTHERPETIC NEURALGIA; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SEIZURE; SOCIAL PHOBIA; SOMNOLENCE; TERATOGENICITY; TONIC CLONIC SEIZURE; TRIGEMINUS NEURALGIA;

ANTICONVULSANTS; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME;

EID: 84864127730     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.35438     Document Type: Review

References (195)

1. Abdulrazzaq Y, Bastaki S, Padmanabhan R. 1997. Teratogenic effects of vigabatrin in to mouse fetuses. Teratology 55: 165-176.
2. Abela D, Howe A, Oakes D, Webster W. 2005. Maternal antioxidant supplementation does not reduce the incidence of phenytoin-induced cleft lip and related malformations in rats. Birth Defects Res B Dev Reprod Toxicol 74: 201-206.
3. Adab N, Kini U, Vinten J, Ayres J, Baker G, Clayton-Smith J, Coyle H, Fryer A, Gorry J, Gregg J, Mawer G, Nicolaides P, Pickering L, Tunnicliffe L, Chadwick DW. 2004. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 75: 1575-1583.
4. Afshar M, Hassanzadeh-Taheri MM, Moallem SA, Tamizi A, Golalipour MJ. 2009. Teratogenic effects of gabapentin on the skeletal system of Balb/C mice fetuses. Neurosciences (Riyadh) 14: 239-244.
5. Afshar M, Moallem S, Houshang Mohammadpour A, Shiravi A, Majid Jalalian S, Jafar Golalipour M. 2010. Teratogenic effects of carbamazepine on embryonic eye development in pregnant mice. Cutan Ocul Toxicol 29: 10-15.
6. Alonso-Aperte E, Ubeda N, Achon M, Perez-Miguelsanz J, Varela-Moreiras G. 1999. Impaired methionine synthesis and hypomethylation in rats exposed to valproate during gestation. Neurology 52: 750-756.
7. Artama M, Auvinen A, Raudaskoski T, Isojärvi I, Isojärvi J. 2005. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 64: 1874-1878.
8. Artama M, Ritvanen A, Gissler M, Isojarvi J, Auvinen A. 2006. Congenital structural anomalies in offspring of women with epilepsy a population-based cohort study in finland. Int J Epidemiol 35: 280-287.
9. Bastaki SM, Padmanabhan R, Abdulrazzaq YM, Chandranath SI, Shafiullah M. 2001. Studies on the teratogenic effects of lamotrigine in mouse fetuses. Front Fetal Health 3: 295.
10. Bennett GD, Amore BM, Finnell RH, Wlodarczyk B, Kalhorn TF, Skiles GL, Nelson SD, Slattery JT. 1996. Teratogenicity of carbamazepine-10, 11-epoxide and oxcarbazepine in the SWV mouse. J Pharmacol Exp Ther 279: 1237-1242.
11. Bialer M. 1999. Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs. J Control Release 62: 187-192.
12. Bialer M. 2011. Chemical properties of antiepileptic drugs (AEDs). Adv Drug Deliv Rev DOI: 10.1016/j.addr.2011.11.006.
13. Blake DA, Martz F. 1980. Covalent binding of phenytoin metabolites in fetal tissue. In: Hassell TM, Johnston M, Dudley KH, editors. Phenytoin-induced teratology and gingival pathology. New York: Raven Press. pp 75-80.
14. Bromley RL, Baker GA, Meador KJ. 2009. Cognitive abilities and behaviour of children exposed to antiepileptic drugs in utero. Curr Opin Neurol 22: 162-166.
15. Candito M, Naimi M, Boisson C, Rudigoz JC, Gaucherand P, Gueant JL, Luton D, Van Obberghen E. 2007. Plasma vitamin values and antiepileptic therapy: Case reports of pregnancy outcomes affected by a neural tube defect. Birth Defects Res A Clin Mol Teratol 79: 62-64.
16. Canger R, Battino D, Canevini MP, Fumarola C, Guidolin L, Vignoli A, Mamoli D, Palmieri C, Molteni F, Granata T, Hassibi P, Zamperini P, Pardi G, Avanzini G. 1999. Malformations in offspring of women with epilepsy: A prospective study. Epilepsia 40: 1231-1236.
17. Carey JC, Martinez L, Balken E, Leen-Mitchell M, Robertson J. 2009. Determination of human teratogenicity by the astute clinician method: Review of illustrative agents and a proposal of guidelines. Birth Defects Res A Clin Mol Teratol 85: 63-68.
18. Cascade E, Kalali AH, Weisler RH. 2008. Varying uses of anticonvulsant medications. Psychiatry 5: 31-33.
19. Chang T, Savory A, Glazko AJ. 1970. A new metabolite of 5, 5-diphenylhydantoin (Dilantin). Biochem Biophys Res Commun 38: 444-449.
20. Chong DJ, Bazil CW. 2010. Update on anticonvulsant drugs. Curr Neurol Neurosci Rep 10: 308-318.
21. Craig J, Morrison P, Morrow J, Patterson V. 1999. Failure of periconceptual folic acid to prevent a neural tube defect in the offspring of a mother taking sodium valproate. Seizure 8: 253-254.
22. Crombie I. 1984. Inherent limitations of the yellow card system for the detection of unsuspected adverse drug reactions. Hum Toxicol 3: 261-269.
23. Cunnington M, Tennis P. 2005. Lamotrigine and the risk of malformations in pregnancy. Neurology 64: 955-960.
24. Dansky LV, Andermann E, Rosenblatt D, Sherwin AL, Andermann F. 1987. Anticonvulsants, folate levels, and pregnancy outcome: A prospective study. Ann Neurol 21: 176-182.
25. Di Renzo F, Cappelletti G, Broccia ML, Giavini E, Menegola E. 2007. Boric acid inhibits embryonic histone deacetylases: A suggested mechanism to explain boric acid-related teratogenicity. Toxicol Appl Pharmacol 220: 178-185.
26. Diav-Citrin O, Shechtman S, Bar-Oz B, Cantrell D, Arnon J, Ornoy A. 2008. Pregnancy outcome after in utero exposure to valproate: Evidence of dose relationship in teratogenic effect. CNS Drugs 22: 325-334.
27. Diepold C, Eyer P, Kampffmeyer H, Reinhardt K. 1982. Reactions of aromatic compounds with thiols. In: Snyder R, Parke DV, Kocsis JJ, Jollow DJ, Gibson CG, Witmer CM, editors. Biological reactive intermediates: 2: Chemical mechanisms and biological effects, Volume B. New York: Plenum Press. pp 1173-1181.
28. Ehlers K, Sturje H, Merker HJ, Nau H. 1992. Valproic acid-induced spina bifida a mouse model. Teratology 45: 145-1154.
29. Eikel D, Lampen A, Nau H. 2006. Teratogenic effects mediated by inhibition of histone deacetylases: Evidence from quantitative structure activity relationships of 20 valproic acid derivatives. Chem Res Toxicol 19: 272-278.
30. Eke T, Talbot JF, Lawden MC. 1997. Severe persistent visual field constriction associated with vigabatrin. BMJ 314: 180-181.
31. El-Sayed MG, Aly AE, Kadri M, Moustafa AM. 1983. Comparative study on the teratogenicity of some antiepileptics in the rat. East Afr Med J 60: 407-415.
32. Elshove J. 1969. Ceft palate in the offspring of female mice treated with phenytoin. Lancet 2: 1074.
33. Eluma FO, Sucheston ME, Hayes TG, Paulson RB. 1981. The teratogenic effects of carbamazepine in the CD-I mouse fetus. Teratology 23: 32 A33.
34. Eluma FO, Sucheston ME, Hayes TG, Paulson RB. 1984. Teratogenic effects of dosage levels and time of administration of carbamazepine, sodium valproate, and diphenylhydantoin on craniofacial development in the CD-1 mouse fetus. J Craniofac Genet Dev Biol 4: 191-1210.
35. Emmanouil-Nikoloussi EN, Foroglou NG, Kerameos-Foroglou CH, Thliveris JA. 2004. Effect of valproic acid on fetal and maternal organs in the mouse: A morphological study. Morphologie 88: 41-45.
36. Englund M, Hyllienmark L, Brismar T. 2011. Effect of Valproate, Lamotrigine and Levetiracetam on Excitability and Firing Properties of CA1 Neurons in Rat Brain Slices. Cell Mol Neurobiol 31: 645-652.
37. FDA. Drug Safety Communication: Children born to mothers who took Valproate products while pregnant may have impaired cognitive development. 2011.
38. Finnell RH. 1981. Phenytoin-induced teratogenesis: A mouse model. Science 211: 483-484.
39. Finnell RH, Chernoff GF. 1984. Variable patterns of malformation in the mouse fetal hydantoin syndrome. Am J Med Genet 19: 463-471.
40. Finnell RH, Mohl VK, Bennett GD, Taylor SM. 1986a. Failure of epoxide formation to influence carbamazepine-induced teratogenesis in a mouse model. Teratog Carcinog Mutagen 6: 393-401.
41. Finnell RH, Moon SP, Abbott LC, Golden JA, Chernoff GF. 1986b. Strain differences in heat-induced neural tube defects in mice. Teratology 33: 247-252.
42. Finnell RH, Shields HE, Taylor SM, Chernoff GF. 1987a. Strain differences in phenobarbital-induced teratogenesis in mice. Teratology 35: 177-185.
43. Finnell RH, Shields HE, Chenroff GF. 1987b. Variable patterns in anticonvulsant drug-induced malformations in mice: Comparisons of Phenytoin and Phenobarbital. Teratog Carcinog Mutagen 7: 541-549.
44. Finnell RH, Bennett GD, Karras SB, Mohl VK. 1988. Common hierarchies of susceptibility to the induction of neural tube defects in mouse embryos by valproic acid and its 4-propyl-4-pentenoic acid metabolite. Teratology 38: 313-320.
45. Finnell RH, van Waes M, Musselman A, Kerr BM, Levy RH. 1993. Differences in the patterns of phenytoin-induced malformations following stiripentol coadministration in three inbred mouse strains. Reprod Toxicol 7: 439-448.
46. Finnell RH, Kerr BM, van Waes M, Steward RL, Levy RH. 1994. Protection from phenytoin-induced congenital malformations by coadministration of the antiepileptic drug stiripentol in a mouse model. Epilepsia 35: 141-148.
47. Finnell RH, Bennett GD, Slattery JT, Amore BM, Bajpai M, Levy RH. 1995. Effect of treatment with phenobarbital and stiripentol on carbamazepine-induced teratogenicity and reactive metabolite formation. Teratology 52: 324-332.
48. Finnell RH, Bennett GD, Mather GG, Wlodarczyk B, Bajpai M, Levy RH. 1999. Effect of stiripentol dose on phenytoin-induced teratogenesis in a mouse model. Reprod Toxicol 13: 85-91.
49. French JA. 1999. Vigabatrin. Epilepsia 40: 11-16.
50. Fritz H, Muller D, Hess R. 1976. Comparative study of the teratogenicity of phenobarbitone, diphenylhydantoin and carbamazepine in mice. Toxicology 6: 323-330.
51. Gillard M, Fuks B, Michel P, Vertongen P, Massingham R, Chatelain P. 2003. Binding characteristics of [3H]ucb 30889 to levetiracetam binding sites in rat brain. Eur J Pharmacol 478: 1-9.
52. Gotfryd K, Hansen M, Kawa A, Ellerbeck U, Nau H, Berezin V, Bock E, Walmod PS. 2011. The Teratogenic potencies of valproic acid derivatives and their effects on biological end-points are related to changes in histone deacetylase and Erk1/2 activities. Basic Clin Pharmacol Toxicol 109: 164-174.
53. Gottlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T. 2001. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978.
54. Griffin RJ, Dudley CN, Cunningham ML. 1996. Biochemical effects of the mouse hepatocarcinogen oxazepam: Similarities to phenobarbital. Fundam Appl Toxicol 29: 147-154.
55. Gurvich N, Berman MG, Wittner BS, Gentleman RC, Klein PS, Green JB. 2005. Association of valproate-induced teratogenesis with histone deacetylase inhibition in vivo. FASEB J 19: 1166-1168.
56. Hanson JW. 1986. Teratogen update: Fetal hydantoin effects. Teratology 33: 349-353.
57. Hanson JW, Smith DW. 1975. The fetal hydantoin syndrome. J Pediatr 87: 285-290.
58. Hanson JW, Smith DW. 1976. Fetal hydantoin syndrome. Lancet 1: 692.
59. Harbison RD. 1978. Chemical-biological reactions common to teratogenesis and mutagenesis. Environ Health Perspect 24: 87-100.
60. Harbison RD, Becker BA. 1969. Relation of dosage and time of administration of diphenylhydantoin to its teratogenic effect in mice. Teratology 2: 305-311.
61. Harbison RD, Becker BA. 1972. Diphenylhydantoin teratogenicity in rats. Toxicol Appl Pharmacol 22: 193-200.
62. Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, Wiebe S, Thurman D, Koppel BS, Kaplan PW, Robinson JN, Hopp J, Ting TY, Gidal B, Hovinga CA, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Hirtz D, Le Guen C. 2009. Management issues for women with epilepsy-focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the quality standards subcommittee and therapeutics and technology subcommittee of the american academy of neurology and the american epilepsy society. Epilepsia 50: 1237-1246.
63. Hardman JG, Limbird LE, Gilman AG. 2001. Goodman and Gilman's: The pharmacological basis of therapeutics. New York: McGraw-Hill.
64. Hendrickx AG, Nau H, Binkerd P, Rowland JM, Rowland JR, Cukierski MJ, Cukierski MA. 1988. Valproic acid developmental toxicity and pharmacokinetics in the rhesus monkey: An interspecies comparison. Teratology 38: 329-345.
65. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. 2000. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 343: 1608-1614.
66. Hernandez-Diaz S, Smith CR, Wyzszynski D. 2007. Risk of major malformations among infants exposed to carbamazepine during pregnancy. Proceedings of the 47th Teratology Society Meeting. Birth Defect Research (Part A) 79 p.357.
67. Hernandez-Diaz S, Mittendorf R, Holmes LB. 2010. Comparative Safety of Topiramate During Pregnancy. Birth Defects Research (Part A), Proceedings of the 50th Teratology Society Meeting 88 p.408.
68. Hiilesmaa VK, Teramo K, Granstrom M, Bardy AH. 1983. Serum folate concentrations during pregnancy in women with epilepsy: Relation to antiepileptic drug concentrations, number of seizures, and fetal outcome. Br Med J 287: 577-579.
69. Hill DS, Wlodarczyk BJ, Palacios AM, Finnell RH. 2010. Teratogenic effects of antiepileptic drugs. Expert Rev Neurother 10: 943-959.
70. Hoffman JI, Kaplan S. 2002. The incidence of congenital heart disease. J Am Coll Cardiol 39: 1890-1900.
71. Holmes LB, Harvey EA, Coull BA, Huntington KB, Khoshbin S, Hayes AM, Ryan LM. 2001. The teratogenicity of anticonvulsant drugs. N Engl J Med 344: 1132-1138.
72. Holmes LB, Wyszynski DF, Lieberman E. 2004. The AED (antiepileptic drug) pregnancy registry: A 6-year experience. Arch Neurol 61: 673-678.
73. Holmes LB, Baldwin EJ, Smith CR, Habecker E, Glassman L, Wong SL, Wyszynski DF. 2008a. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 70: 2152-2158.
74. Holmes LB, Smith CR, Hernandez-Diaz S. 2008b. Pregnancy registries; larger samples sizes essential: 48th Annual Meeting of the Teratology Society. Birth Defects Research (Part B). Proceedings of the 48th annual meeting of the teratology society 82, p 307.
75. Hsieh CL, Wang HE, Tsai WJ, Peng CC, Peng RY. 2012. Multiple point action mechanism of valproic acid-teratogenicity alleviated by folic acid, vitamin C, And N-acetylcysteine in chicken embryo model. Toxicology 291: 32-42.
76. Hunt S, Craig J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, Irwin B, Morrison PJ, Morrow J. 2006. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 67: 1876-1879.
77. Hunt S, Russell A, Smithson WH, Parsons L, Robertson I, Waddell R, Irwin B, Morrison PJ, Morrow J, Craig J. 2008. Topiramate in pregnancy: Preliminary experience from the UK epilepsy and pregnancy register. Neurology 71: 272-276.
78. Hunt SJ, Craig JJ, Morrow JI. 2009. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 72: 1108.
79. Isoherranen N, Spiegelstein O, Bialer M, Zhang J, Merriweather M, Yagen B, Roeder M, Triplett AA, Schurig V, Finnell RH. 2003. Developmental outcome of levetiracetam, its major metabolite in humans, 2-pyrrolidinone N-butyric acid, and its enantiomer (R)-a-ethyl-oxo-pyrrolidine acetamide in a mouse model of teratogenicity. Epilepsia 44: 1280-1288.
80. Jentink J, Bakker MK, Nijenhuis CM, Wilffert B, de Jong-van den Berg LT. 2010. Does folic acid use decrease the risk for spina bifida after in utero exposure to valproic acid? Pharmacoepidemiol Drug Saf 19: 803-807.
81. Jerina DM, Daly JW. 1974. Arene oxides: A new aspect of drug metabolism. Science 185: 573-582.
82. Kaaja E, Kaaja R, Hiilesmaa V. 2003. Major malformations in offspring of women with epilepsy. Neurology 60: 575-579.
83. Kaneko S, Battino D, Andermann E, Wada K, Kan R, Takeda A, Nakane Y, Ogawa Y, Avanzini G, Fumarola C, Granata T, Molteni F, Pardi G, Minotti L, Canger R, Dansky L, Oguni M, Lopes-Cendas I, Sherwin A, Andermann F, Seni MH, Okada M, Teranishi T. 1999. Congenital malformations due to antiepileptic drugs. Epilepsy Res 33: 145-158.
84. Kantola-Sorsa E, Gaily E, Isoaho M, Korkman M. 2007. Neuropsychological outcomes in children of mothers with epilepsy. J Int Neuropsychol Soc 3: 642-652.
85. Kaufmann D, Yagen B, Minert A, Wlodarczyk B, Finnell RH, Schurig V, Devor M, Bialer M. 2010. Evaluation of the antiallodynic, teratogenic and pharmacokinetic profile of stereoisomers of valnoctamide, an amide derivative of a chiral isomer of valproic acid. Neuropharmacology 58: 1228-1236.
86. Khera KS. 1979. A teratogenicity study on hydroxyurea and diphenylhydantoin in cats. Teratology 20: 447-452.
87. Kjaer D, Horvath-Puhó E, Christensen J, Vestergaard M, Czeizel AE, Sørensen HT, Olsen J. 2008. Antiepileptic drug use, folic acid supplementation, and congenital abnormalities: A population-based case-control study. BJOG 115: 98-103.
88. Kluck RM, Cannell GR, Hooper WD, Eadie MJ, Dickinson RG. 1988. Disposition of phenytoin and phenobarbitone in the isolated perfused human placenta. Clin Exp Pharmacol Physiol 15: 827-836.
89. Kubow S, Wells PG. 1989. In vitro bioactivation of phenytoin to a reactive free radical intermediate by prostaglandin synthetase, horseradish peroxidase, and thyroid peroxidase. Mol Pharmacol 35: 504-511.
90. Lawthom C, Smith PE, Wild JM. 2009. In utero exposure to vigabatrin: No indication of visual field loss. Epilepsia 50: 318-321.
91. Leach MJ, Marden CM, Miller AA. 1986. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia 27: 490-497.
92. Lewis DP, Van Dyke DC, Willhite LA, Stumbo PJ, Berg MJ. 1995. Phenytoin-folic acid interaction. Ann Pharmacother 29: 726-735.
93. Lindhout D, Hoppener RJ, Meinardi H. 1984. Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (of carbamazepine). Epilepsia 25: 77-83.
94. Linnebank M, Moskau S, Semmler A, Widman G, Stoffel-Wagner B, Weller M, Elger CE. 2011. Antiepileptic drugs interact with folate and vitamin B12 serum levels. Ann Neurol 69: 352-359.
95. Long L. 2003. Levetiracetam monotherapy during pregnancy - a case series. Epilepsy Behav 4: 447-448.
96. Loughnan PM, Gold H, Vance JC. 1973. Phenytoin teratogenicity in man. Lancet 1: 70-72.
97. Lum JT, Wells PG. 1986. Pharmacological studies on the potentiation of phenytoin teratogenicity by acetaminophen. Teratology 33: 53-72.
98. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B. 2004. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci 101: 9861-9866.
99. Lyseng-Williamson KA, Yang LP. 2007. Topiramate: a review of its use in the treatment of epilepsy. Drugs 67: 2231-2256.
100. Manent JB, Jorquera I, Mazzucchelli I, Depaulis A, Perucca E, Ben-Ari Y, Represa A. 2007. Fetal exposure to gaba-acting antiepileptic drugs generates hippocampal and cortical dysplasias. Epilepsia 48: 684-693.
101. Manent JB, Jorquera I, Franco V, Ben-Ari Y, Perucca E, Represa A. 2008. Antiepileptic drugs and brain maturation: Fetal exposure to lamotrigine generates cortical malformations in rats. Epilepsy Res 78: 131-139.
102. Martz F, Failinger C III, Blake DA. 1977. Phenytoin teratogenesis: Correlation between embryopathic effect and covalent binding of putative arene oxide metabolite in gestational tissue. J Pharmacol Exp Ther 203: 231-239.
103. Massey KM. 1966. Teratogenic effects of diphenylhydantoin sodium. J Oral Ther Pharmacol 2: 380-385.
104. Matalon S, Schechtman S, Goldzweig G, Ornoy A. 2002. The teratogenic effect of carbamazepine: A meta-analysis of 1255 exposures. Reprod Toxicol 16: 9-17.
105. Matar KM, Marafie NA. 2011. Effect of pregnancy on topiramate pharmacokinetics in rabbits. Xenobiotica 41: 416-421.
106. Mawer G, Briggs M, Baker GA, Bromley R, Coyle H, Eatock J, Kerr L, Kini U, Kuzmyshcheva L, Lucas SB, Wyatt L, Clayton-Smith J, Liverpool and Manchester Neurodevelopment Group. 2010. Pregnancy with epilepsy: Obstetric and neonatal outcome of a controlled study. Seizure 19: 112-119.
107. McClain RM, Langhoff L. 1980. Teratogenicity of diphenylhydantoin in the New Zealand white rabbit. Teratology 21: 371-379.
108. McDevitt JM, Gautieri RF, Mann DE Jr. 1981. Comparative teratogenicity of cortisone and phenytoin in mice. J Pharm Sci 70: 631-634.
109. McLean MJ, Macdonald RL. 1986. Carbamazepine and 10, 11-epoxycarbamazepine produce use- and voltage-dependent limitation of rapidly firing action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 238: 727-738.
110. McVearry KM, Gaillard WD, VanMeter J, Meador KJ. 2009. A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy Behav 16: 609-616.
111. Meador KJ, Baker GA, Finnell RH, Kalayjian LA, Liporace JD, Loring DW, Mawer G, Pennell PB, Smith JC, Wolff MC. 2006. In utero antiepileptic drug exposure: Fetal death and malformations. Neurology 67: 407-412.
112. Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C. 2008a. Pregnancy outcomes in women with epilepsy: A systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res 81: 1-13.
113. Meador KJ, Pennell PB, Harden CL, Gordon JC, Tomson T, Kaplan PW, Holmes GL, French JA, Hauser WA, Wells PG, Cramer JA. 2008b. Pregnancy registries in epilepsy: A consensus statement on health outcomes. Neurology 71: 1109-1117.
114. Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW. 2009a. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 360: 1597-1605.
115. Meador KJ, Penovich P, Baker GA, Pennell PB, Bromfield E, Pack A, Liporace JD, Sam M, Kalayjian LA, Thurman DJ, Moore E, Loring DW. 2009b. Antiepileptic drug use in women of childbearing age. Epilepsy Behav 15: 339-343.
116. Meador KJ, Baker GA, Browning N, Cohen MJ, Clayton-Smith J, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW, NEAD Study Group. 2011. Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain 134: 396-404.
117. Menegola E, Broccia ML, Nau H, Prati M, Ricolfi R, Giavini E. 1996. Teratogenic effects of sodium valproate in mice and rats at midgestation and at term. Teratog Carcinog Mutagen 16: 97-108.
118. Menegola E, Di Renzo F, Broccia ML, Prudenziati M, Minucci S, Massa V, Giavini E. 2005. Inhibition of histone deacetylase activity on specific embryonic tissues as a new mechanism for teratogenicity. Birth Defects Res B Dev Reprod Toxicol 74: 392-398.
119. Menegola E, Di Renzo F, Broccia ML, Giavin E. 2006. Inhibition of histone deacetylase as a new mechanism of teratogenesis. Birth Defects Res C Embryo Today 78: 345-353.
120. Mercier-Parot L, Tuchmann-Duplessis H. 1974. The dysmorphogenic potential of phenytoin: Experimental observations. Drugs 8: 340-353.
121. Mishara A, Singh M. 2008. Topiramate induced histopathological changes in placenta of rats. Indian J Exp Biol 46: 715-719.
122. Moldeus P, Jemstrom B. 1983. Interaction of glutathione with reactive intermediates. In: Larsson A, Orrenius S, Holmgren A, Mannervik B, editors. Functions of glutathione: Biochemical, physiological, toxicological and clinical aspects. New York: Raven Press. pp 99-108.
123. Montouris G. 2003. Gabapentin exposure in human pregnancy: Results from the gabapentin pregnancy registry. Epilepsy Behav 4: 310-317.
124. Montouris G. 2005. Safety of the newer antiepileptic drug oxcarbazepine during pregnancy. Curr Med Res Opin 21: 693-701.
125. Morrell MJ. 1998. Guidelines for the care of women with epilepsy. Neurology 51: S21-27.
126. Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, Irwin B, McGivern RC, Morrison PJ, Craig J. 2006. Malformation risks of antiepileptic drugs in pregnancy: A prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 77: 193-198.
127. Morrow J, Hunt S, Russell A, Smithson W, Parsons L, Robertson I, Waddell R, Irwin B, Morrison P, Craig J. 2009. Folic acid use and major congenital malformations in offspring of women with epilepsy: A prospective study from the uk epilepsy and pregnancy register. J Neurol Neurosurg Psychiatry 80: 506-511.
128. Munoz-Garcia D, Del Ser T, Bermejo F, Sarabia-Garcia F. 1983. Folic acid and vitamin B12 in long-term anticonvulsant therapy. Mt Sinai J Med 50: 517-521.
129. Nadebaum C, Anderson VA, Vajda F, Reutens DC, Barton S, Wood AG. 2011. Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology 76: 719-726.
130. Nambisan M, Wyszynski DF, Holmes LB. 2003. No evidence of a protective effect due to periconceptional folic acid (pcfa) intake on risk for congenital anomalies in the offspring of mothers exposed to antiepileptic drugs (aeds). Birth Defects Res A Clin Mol Teratol 64: 961-965.
131. Nau H. 1985. Teratogenic valproic acid concentrations: Infusion by implanted minipumps vs. conventional injection regimen in the mouse. Toxicol Appl Pharmacol 80: 243-250.
132. Nau H, Hendrickx G. 1987. Valproic acid teratogenesis. ISI Atlas Sci Pharmacol 1: 52-56.
133. Nau H, Loscher W. 1986. Pharmacologic evaluation of various metabolites and analogs of valproic acid: Teratogenic potencies in mice. Fundam Appl Toxicol 6: 669-676.
134. Niedermeyer E. 1983. Epilepsy guide: Diagnosis and treatment of epileptic seizure disorders. Munich, Germany: Urban and Schwarzenberg.
135. Ogawa Y, Kaneko S, Otani K, Fukushima Y. 1991. Serum folic acid levels in epileptic mothers and their relationship to congenital malformations. Epilepsy Res 8: 75-78.
136. Ohman I, Sabers A, de Flon P, Luef G, Tomson T. 2009. Pharmacokinetics of topiramate during pregnancy. Epilepsy Res 87: 124-129.
137. Ornoy A. 2009. Valproic acid in pregnancy: How much are we endangering the embryo and fetus? Reprod Toxicol 28: 1-10.
138. Ornoy A, Zvi N, Arnon J, Wajnberg R, Shechtman S, Diav-Citrin O. 2008. The outcome of pregnancy following topiramate treatment: A study on 52 pregnancies. Reprod Toxicol 25: 388-389.
139. Padmanabhan R, Abdulrazzaq YM, Bastaki SM, Shafiullah M, Chandranath SI. 2003. Experimental studies on reproductive toxicologic effects of lamotrigine in mice. Birth Defects Res B Dev Reprod Toxicol 68: 428-438.
140. Padmanabhan R, Abdulrazzaq YM, Bastaki SM, Shafiullah MM. 2008. Intrauterine growth restriction and skeletal variations in mouse fetuses induced by vigabatrin administered at preimplantation stages of development. Congenit Anom (Kyoto) 48: 29-39.
141. Padmanabhan R, Abdulrazzaq YM, Bastaki SM, Nurulain M, Shafiullah M. 2010. Vigabatrin (VGB) administered during late gestation lowers maternal folate concentration and causes pregnancy loss, fetal growth restriction and skeletal hypoplasia in the mouse. Reprod Toxicol 29: 366-377.
142. Paulson RB, Paulson GW, Jreissaty S. 1979. Phenytoin and carbamazepine in production of cleft palates in mice. Comparison of teratogenic effects. Arch Neurol 36: 832-836.
143. Peng BW, Justice JA, Zhang K, Li JX, He XH, Sanchez RM. 2011. Gabapentin promotes inhibition by enhancing hyperpolarization-activated cation currents and spontaneous firing in hippocampal CA1 interneurons. Neurosci Lett 494: 19-23.
144. Pennell PB. 2003. Antiepileptic drug pharmacokinetics during pregnancy and lactation. Neurology 61: 35-42.
145. Pennell PB. 2006. EURAP outcomes for seizure control during pregnancy: Useful and encouraging data. Epilepsy Curr 6: 186-188.
146. Pessah N, Kaufmann D, Yagen B, Hen N, Wlodarczyk B, Finnell RH, Bialer M. 2010. Comparative pharmacodynamic and pharmacokinetic analysis of two anticonvulsant halo derivatives of 2, 2, 3, 3-tetramethylcyclopropanecarboxamide, an amide of a cyclic analog of valproic acid. Epilepsia 51: 1944-1953.
147. Petrere JA, Anderson JA, Sakowski R, Fitzgerald JE, de la Iglesia FA. 1986. Teratogenesis of calcium valproate in rabbits. Teratology 34: 263-269.
148. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. 2001. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734-36741.
149. Pittschieler S, Brezinka C, Jahn B, Trinka E, Unterberger I, Dobesberger J, Walser G, Auckenthaler A, Embacher N, Bauer G, Luef G. 2008. Spontaneous abortion and the prophylactic effect of folic acid supplementation in epileptic women undergoing antiepileptic therapy. J Neurol 255: 1926-1931.
150. Prakash Prabhu LV, Nasar MA, Rai R, Madhyastha S, Singh G. 2007. Lamotrigine in pregnancy: Safety profile and the risk of malformations. Singapore Med J 48: 880-883.
151. Prakash LV, Rai R, Pai MM, Yadav SK, Madhyastha S, Goel RK, Singh G, Nasar MA. 2008. Teratogenic effects of the anticonvulsant gabapentin in mice. Singapore Med J 49: 47-53.
152. Rey E, Pons G, Olive G. 1992. Vigabatrin. Clin Pharmacokinet 23: 267-278.
153. Riebeling C, Pirow R, Becker K, Buesen R, Eikel D, Kaltenhäuser J, Meyer F, Nau H, Slawik B, Visan A, Volland J, Spielmann H, Luch A, Seiler A. 2011. The embryonic stem cell test as tool to assess structure-dependent teratogenicity: The case of valproic acid. Toxicol Sci 120: 360-370.
154. Sabers A, Tomson T. 2009. Managing antiepileptic drugs during pregnancy and lactation. Curr Opin Neurol 22: 157-161.
155. Samrén EB, van Duijn CM, Christiaens GC, Hofman A, Lindhout D. 1999. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 46: 739-746.
156. Shallcross R, Bromley RL, Irwin B, Bonnett LJ, Morrow J, Baker GA, Liverpool Manchester Neurodevelopment Group, UK Epilepsy Pregnancy Register. 2011. Child development following in utero exposure: Levetiracetam vs. sodium valproate. Neurology 76: 383-389.
157. Shimshoni JA, Yagen B, Pessah N, Wlodarczyk B, Finnell RH, Bialer M. 2008. Anticonvulsant profile and teratogenicity of 3, 3-dimethylbutanoylurea: A potential for a second generation drug to valproic acid. Epilepsia 49: 1202-1212.
158. Sobol E, Yagen B, White SH, Wilcox KS, Lamb JG, Pappo O, Wlodarczyk BJ, Finnell RH, Bialer M. 2006. Preclinical evaluation of 2, 2, 3, 3-tetramethylcyclopropanecarbonyl-urea, a novel, second generation to valproic acid, antiepileptic drug. Neuropharmacology 51: 933-946.
159. Sorri I, Herrgard E, Viinikainen K, Paakkonen A, Heinonen S, Kalviainen R. 2005. Ophthalmologic and neurologic findings in two children exposed to vigabatrin in utero. Epilepsy Res 65: 117-120.
160. Stefani A, Spadoni F, Bernardi G. 1998. Gabapentin inhibits calcium currents in isolated rat brain neurons. Neuropharmacology 37: 83-91.
161. Strickler SM, Dansky LV, Miller MA, Seni MH, Andermann E, Spielberg SP. 1985. Genetic predisposition to phenytoin induced birth defects. Lancet 2: 746-749.
162. Sulik KK, Johnston MC, Ambrose LJ, Dorgan D. 1979. Phenytoin (dilantin)-induced cleft lip and palate in A/J mice: A scanning and transmission electron microscopic study. Anat Rec 195: 243-255.
163. Sullivan FM, McElhatton PR. 1977. A comparison of the teratogenic activity of the antiepileptic drugs carbamazepine, clonazepam, ethosuximide, phenobarbital, phenytoin, and primidone in mice. Toxicol Appl Pharmacol 40: 365-378.
164. Surges R, Freiman TM, Feuerstein TJ. 2003. Gabapentin increases the hyperpolarization-activated cation current Ih in rat CA1 pyramidal cells. Epilepsia 44: 150-156.
165. Tecoma ES. 1999. Oxcarbazepine. Epilepsia 40: S37-S46.
166. Ten Berg K, Samrén B, van Oppen C, Martijn E, Lindhoudt D. 2005. Levetiracetam use and pregnancy outcome. Reprod Toxicol 20: 175-178.
167. Thomas SV, Ajaykumar B, Sindhu K, Francis E, Namboodiri N, Sivasankaran S, Tharakan JA, Sarma PS. 2008a. Cardiac malformations are increased in infants of mothers with epilepsy. Pediatr Cardiol 29: 604-608.
168. Thomas SV, Ajaykumar B, Sindhu K, Nair MK, George B, Sarma PS. 2008b. Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy Behav 13: 229-236.
169. Thomson/Micromedex. 2007. Drug information for the health care professional. 1: 1816
170. Tomson T, Battino D. 2009a. The Management of epilepsy in pregnancy. In: Shorvon S, Pedley TA, editors. The blue books of neurology series: The epilepsies 3, Vol. 33. Pensylvania: Saunders Elsevier.
171. Tomson T, Battino D. 2009b. Teratogenic effects of antiepileptic medications. Neurol Clin 27: 993-1002.
172. Tomson T, Lindbom U, Ekqvist B, Sundqvist A. 1994. Disposition of carbamazepine and phenytoin in pregnancy. Epilepsia 35: 131-135.
173. Tomson T, Palm R, Källén K, Ben-Menachem E, Söderfeldt B, Danielsson B, Johansson R, Luef G, Ohman I. 2007. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia 48: 1111-1116.
174. Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, Perucca E, Vajda F, EURAP study group. 2011. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 10: 609-617.
175. Vajda FJ, Eadie MJ. 2005. Maternal valproate dosage and foetal malformations. Acta Neurol Scand 112: 137-143.
176. Vajda FJ, Hitchcock A, Graham J, Solinas C, O'Brien TJ, Lander CM, Eadie MJ. 2006. Foetal malformations and seizure control: 52 months data of the australian pregnancy registry. Eur J Neurol 13: 645-654.
177. Vajda FJ, Hitchcock A, Graham J, O'Brien T, Lander C, Eadie MJ. 2007. The Australian Register of Antiepileptic Drugs in Pregnancy: The first 1002 pregnancies. Aust NZ J Obstet Gynaecol 47: 468-474.
178. Vajda FJ, Graham JE, Hitchcock AA, O'Brien TJ, Lander CM, Eadie MJ. 2010. Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure 19: 558-561.
179. Vajda FJ, Graham J, Roten A, Lander CM, O'Brien TJ, Eadie M. 2012. Teratogenicity of the newer antiepileptic drugs-The Australian experience. J Clin Neurosci 19: 57-59.
180. Vinten J, Bromley RL, Taylor J, Adab N, Kini U, Baker GA, Liverpool and Manchester Neurodevelopment Group. 2009. The behavioral consequences of exposure to antiepileptic drugs in utero. Epilepsy Behav 14: 197-201.
181. Vorhees CV. 1983. Fetal anticonvulsant syndrome in rats: Dose- and period-response relationships of prenatal diphenylhydantoin, trimethadione and phenobarbital exposure on the structural and functional development of the offspring. J Pharmacol Exp Ther 227: 274-287.
182. Vorhees CV, Acuff KD, Weisenburger WP, Minck DR. 1990. Teratogenicity of carbamazepine in rats. Teratology 41: 311-317.
183. Vorvick L, Luc J, Zieve D. 2010. Epilepsy. Temporal lobe epilepsy; Seizure disorder. In: PubMed Health. Available from
184. Waxman DJ, Azaroff L. 1992. Phenobarbital induction of cytochrome P-450 gene expression. Biochem J 281: 577-592.
185. Wegner C, Nau H. 1992. Alteration of embryonic folate metabolism by valproic acid during organogenesis: Implications for mechanism of teratogenesis. Neurology 42: 17-24.
186. Wells PG, Harbison RD. 1980. Significance of the phenytoin reactive arene oxide intermediate, its oxepin tautomer, and clinical factors modifying their roles in phenytoin-induced teratology. In: Hassell TM, Johnston MC, Dudley KH, editors. Phenytoin-induced teratology and gingival pathology. New York: Raven Press. pp 83-108.
187. Wells PG, Vo HP. 1989. Effects of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate on phenytoin-induced embryopathy in mice. Toxicol Appl Pharmacol 97: 398-405.
188. Werler MM, Ahrens KA, Bosco JL, Mitchell AA, Anderka MT, Gilboa SM, Holmes LB, National Birth Defects Prevention Study. 2011. Use of antiepileptic medications in pregnancy in relation to risks of birth defects. Ann Epidemiol 21: 842-850.
189. Wide K, Winbladh B, Kallen B. 2004. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: A nation-wide, population-based register study. Acta Paediatr 93: 174-176.
190. Wiltse J. 2005. Mode of action: Inhibition of histone deacetylase, altering WNTdependent gene expression, and regulation of b-catenin - developmental effects of valproic acid. Crit Rev Toxicol 35: 727-738.
191. Winn LM, Wells PG. 1995. Phenytoin-initiated dna oxidation in murine embryo culture, and embryo protection by the antioxidative enzymes superoxide dismutase and catalase: Evidence for reactive oxygen species-mediated dna oxidation in the molecular mechanism of phenytoin teratogenicity. Mol Pharmacol 48: 112-120.
192. Winn LM, Wells PG. 2002. Evidence for ras-dependent signal transduction in phenytoin teratogenicity. Toxicol Appl Pharmacol 184: 144-152.
193. Wyszynski DF, Nambisan M, Surve T, Alsdorf RM, Smith CR, Holmes LB. 2005. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 64: 961-965.
194. Yerby MS. 2003a. Management issues for women with epilepsy: Neural tube defects and folic acid supplementation. Neurology 61: 23-26.
195. Yerby MS. 2003b. Clinical care of pregnant women with epilepsy: Neural tube defects and folic acid supplementation. Epilepsia 44: 33-40.